NASDAQ:PASG
Passage BIO, Inc.
Passage BIO, Inc. reported net income of −$45.5M in fiscal 2025. The diluted share count rose 3.1%.Summary generated from Passage BIO, Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−113.8%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+3.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −186 | −138 | −108 | −70 | −49 |
| Net income | −185 | −136 | −102 | −65 | −46 |
| Free cash flow | n/a | n/a | n/a | −48 | n/a |
Recent filings
- 8-KEntry into a material agreement
Sep 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 4Insider transaction report
Jun 29, 2026 - 8-KEntry into a material agreement
Jun 24, 2026 - 8-KTermination of a material agreement
May 27, 2026 - 8-KResults of a shareholder vote
May 26, 2026 - 4Insider transaction report
May 21, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026